Premium
An Antibody‐Toxin Conjugate Directed against a Human Mammary Cancer Antigen a
Author(s) -
MONACO MARIE E.,
MACK JOHN,
DUGAN MICHAEL D.,
CERIANI ROBERTO
Publication year - 1986
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.1986.tb16018.x
Subject(s) - conjugate , diphtheria toxin , chemistry , antibody , mammary tumor , monoclonal antibody , toxin , microbiology and biotechnology , toxicity , antigen , antibody drug conjugate , biochemistry , immunology , cancer , biology , medicine , breast cancer , mathematical analysis , mathematics , organic chemistry
A conjugate has been constructed consisting of diphtheria toxin fragment A (DTA) linked to a monoclonal antibody, BLMRL-HMFG-Mc5 (MC5), directed against a mammary cancer antigen. The conjugate retains both binding and DTA enzymatic activity when tested against target MCF-7 cells, although the conjugate binds less well than the unconjugated antibody. The conjugate is toxic to MCF-7 cells. Toxicity is both dose- and time-dependent. Half-maximal toxicity is observed with 2-5 X 10(-8) M conjugate after 5 days of incubation. However, the conjugate need only be in contact with the cells for 1 day in order to effect complete killing by 5 days. The earliest that an effect can be seen on cell growth is 2 days. When tested against WRK-1 rat mammary tumor cells, the conjugate is inactive.